Clinical Features and Risk Factors of Rapidly Progressive Systemic Sclerosis in a Single Center in China: Anti-RNA Polymerase III Antibodies as a Predictor

被引:1
|
作者
Yu, Qiuxia [1 ,2 ]
Zhang, Jin [1 ,2 ]
Fan, Liyi [3 ]
Yu, Tianhang [3 ]
Liu, Bingbing [1 ,2 ]
Ding, Jian [1 ,2 ]
机构
[1] Lihuili Hosp, Ningbo Med Ctr, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[2] Ningbo Univ, Li Huili Hosp, Dept Rheumatol & Clin Immunol, Ningbo 315040, Zhejiang, Peoples R China
[3] Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China
关键词
rapidly progressive systemic sclerosis; clinical characteristics; predictors; anti-RNA polymerase III antibodies; malignancy; AUTOANTIBODIES; INVOLVEMENT;
D O I
10.24976/Discov.Med.202335175.20
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: Systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extend of skin thickening. In this study, we classified a novel subset of SSc defined rapidly progressive systemic sclerosis (RPSSc), which based on the rate of skin thickening progression and the progressive of interstitial lung disease (ILD). We aimed to evaluate RPSSc clinical characteristics and predictive factors in a Chinese single center. Method: Overall, 75 patients diagnosed with SSc, classified into RPSSc (n = 14) and non-rapidly progressive SSc (non-RPSSc, n = 61) were retrospectively included in the study. Clinical characteristics, disease severity and autoantibodies were collected. Logistic regression, least absolute shrinkage, and selection operator (LASSO) regression analysis was used to identify RPSSc predictors. Receiver operating characteristic (ROC) analysis and Delong test was conducted to evaluate and compare different indexes.Results: RPSSc rate was 18.7%. ILD (64.3%), cardiac involvement (42.9%) were the most common organ system involvement of RPSSc, while Raynaud's phenomenon incidence significantly decreased. Disease duration (12 vs 72, months), sex (42.9% vs 11.5%, male %), SSc subset (85.7% vs 27.9%, diffuse cutaneous SSc (dsSSc) %), modified Rodnan total skin score (mRSS) (20.5 vs 6), Raynaud's phenomenon (64.3% vs 98.4%), cardiac involvement (42.9% vs 18%), higher incidence with malignancy (28.6% vs 1.6%) and positive anti-RNA polymerase III antibodies (ARA) (64.3% vs 1.6%) were statistically significant differences among the RPSSc groups and non-RPSSc groups (p < 0.05). Univariate analysis showed that positive ARA, male, dsSSc and malignancy were RPSSc risk factors, while long-disease duration, Raynaud's phenomenon was RPSSc protective factors. ARA was the strongest factor associated to RPSSc (OR 108, 95% CI 11.287-1033.327, p < 0.001). LASSO logistic regression model identified six factors: Disease duration, dsSSc, malignancy, cardiac involvement, positivity of ARA were RPSSc risk factors, Raynaud's phenomenon was RPSSc protective factors.Conclusions: RPSSc is an SSc clinical category which should be accounted for early detection of organ involvement and close follow-up of malignancy. ARA might be used as a predictor for RPSSc and organ involvement.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 50 条
  • [21] ANTI-RNA POL III ANTIBODIES IN SYSTEMIC SCLEROSIS - THE PREVALENCE AND USEFULNESS
    Wielosz, E.
    Dryglewska, M.
    Majdan, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1107 - 1108
  • [22] ANTI-RNA POLYMERASE III AND ANTI PM/SCL ANTIBODIES: PREVALENCE AND CLINICAL ASSOCIATIONS IN A LARGE COHORT OF SPANISH PATIENTS WITH SYSTEMIC SCLEROSIS
    Iniesta, N.
    Espinosa, G.
    Fonollosa, V.
    Tolosa, C.
    Egurbide, M. V.
    Saez Comet, L.
    Ortego, N.
    Rodriguez Carballeira, M.
    Trapiella, L.
    Simeon, C. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1014 - 1014
  • [23] The Association of Weakpositive Anti-RNA Polymerase III Antibodies with the Diagnosis and Complications of Systemic Sclerosis and Other Systemic Autoimmune Diseases
    Badshah, Mashood
    Balaja, Warren
    Donovan, Brannon
    Schmidt, Paul
    Krause, Megan
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3240 - 3242
  • [24] CLINICAL FEATURES OF SYSTEMIC SCLEROSIS ASSOCIATED TO ANTI RNA POLYMERASE III ANTIBODIES IN VALLD'HEBRON HOSPITAL
    Callejas-Moraga, E. L.
    Guillen-Del-Castillo, A.
    Marin-Sanchez, A.
    Fonollosa-Pla, V.
    Balada, E.
    Martin, J.
    Simeon-Aznar, C. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1513 - 1513
  • [25] Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression
    Cavazzana, Ilaria
    Angela, Ceribelli
    Paolo, Airo'
    Stefania, Zingarelli
    Angela, Tincani
    Franco, Franceschini
    AUTOIMMUNITY REVIEWS, 2009, 8 (07) : 580 - 584
  • [26] A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis
    Nihtyanova, Svetlana I.
    Parker, Jennifer C.
    Black, Carol M.
    Bunn, Christopher C.
    Denton, Christopher P.
    RHEUMATOLOGY, 2009, 48 (10) : 1218 - 1221
  • [27] Comparison of systemic sclerosis (SSc) patients with anti-RNA polymerase III and anti-Topoisoimerase I antibodies.
    Mathie, L
    Lucas, M
    Fertig, N
    Medsger, TA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S583 - S583
  • [28] Gastric antral vascular ectasia in systemic sclerosis: Association with anti-RNA polymerase III and negative anti-nuclear antibodies
    Serling-Boyd, Naomi
    Chung, Melody Pei-Shien
    Li, Shufeng
    Becker, Laren
    Fernandez-Becker, Nielsen
    Clarke, John
    Fiorentino, David
    Chung, Lorinda
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (05) : 938 - 942
  • [29] Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis
    Saigusa, Ryosuke
    Asano, Yoshihide
    Nakamura, Kouki
    Miura, Shunsuke
    Ichimura, Yohei
    Takahashi, Takehiro
    Toyama, Tetsuo
    Taniguchi, Takashi
    Noda, Shinji
    Aozasa, Naohiko
    Akamata, Kaname
    Sumida, Hayakazu
    Miyazaki, Miki
    Tamaki, Zenshiro
    Yanaba, Koichi
    Kuwano, Yoshihiro
    Sato, Shinichi
    JOURNAL OF DERMATOLOGY, 2015, 42 (05): : 524 - 527
  • [30] Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
    Benyamine, Audrey
    Bertin, Daniel
    Heim, Xavier
    Granel, Brigitte
    Bardin, Nathalie
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 44 : E42 - E44